MEDLUMICS SL

Their core work

Medlumics is a Madrid-based medtech SME that builds optically-guided medical devices, combining silicon photonic integrated circuits with clinical catheter systems. Their flagship work focuses on real-time, image-guided radiofrequency ablation catheters for treating atrial fibrillation, a cardiac arrhythmia affecting millions. They translate photonics research into manufacturable medical hardware, bridging semiconductor-level optical technology and interventional cardiology. In effect, they turn laboratory photonics into a tool cardiologists can hold in the operating room.

What they specialise in

How they've shifted over time

Between 2016 and 2018 Medlumics worked inside PIX4LIFE as a participant, helping mature a visible-range silicon nitride photonics pilot line shared across life-science users. From 2019 onward they pivoted sharply toward a specific clinical product, coordinating ABLAVIEW to embed that photonics know-how into a catheter for atrial fibrillation ablation. The shift is from generic photonics infrastructure to an owned, vertically integrated cardiology device.

They are moving from photonics technology supplier toward a clinical device company owning a full atrial fibrillation ablation product line.

How they like to work

Medlumics started as a participant in a larger photonics consortium and then graduated to coordinating their own SME Instrument Phase 2 project, signaling growing commercial maturity. Across two projects they worked with 15 partners in 6 countries, indicating a medium-sized network rather than a hub-style collaborator. The pattern suggests a focused team that joins consortia to access technology, then leads when a commercial application is at stake.

They have collaborated with 15 unique partners spread across 6 European countries, a modest but diverse network. The balance of photonics R&D partners and clinical/industrial players reflects their device-commercialization trajectory.

What sets them apart

Very few European SMEs sit at the intersection of silicon photonics manufacturing and interventional cardiology hardware. Medlumics combines credibility earned inside a shared photonics pilot line with the willingness to take coordinator risk on a regulated medical device. For a partner, this means access to photonics-to-clinic integration know-how that is hard to replicate by either a pure photonics foundry or a generic medtech firm.

Highlights from their portfolio

• ABLAVIEW
  Their largest project (€2.47M) and first as coordinator, translating photonics into a clinical atrial fibrillation ablation product.
• PIX4LIFE
  Plugged them into Europe's silicon nitride visible photonics pilot line, providing the technology base for later medical applications.